Catheter Precision, Inc. (VTAK) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Catheter Precision, Inc. is a medical technology company focused on cardiac electrophysiology (EP). Its primary products include the VIVO System (non-invasive 3D cardiac mapping) and LockeT (suture retention device). The company operates as a single reportable segment. As of May 5, 2025, there were 11,017,298 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenues | $143 | $82 |
| Gross Profit | $132 | $77 |
| Operating Loss | $(3,575) | $(2,616) |
| Net Loss | $(4,045) | $(2,675) |
| Net Loss Per Share (Basic/Diluted) | $(0.36) | $(3.60) |
| Cash and Cash Equivalents (End of Period) | $450 | $1,491 |
| Accumulated Deficit | $(296,397) | $(278,384) |
| Net Cash Used in Operating Activities | $(2,338) | $(1,942) |
| Total Liabilities | $16,884 | $16,013 |
Debt and Liquidity: The company holds $1.5 million in current notes payable due to related parties (interest rate 12%, due Jan 31, 2026) and $102 thousand in notes payable for insurance financing. Total current liabilities are $4.09 million against current assets of $0.85 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 74% to $143k, driven by $128k in new LockeT sales. This was partially offset by a 82% decline in VIVO System sales ($15k vs $82k), attributed to reduced sales efforts in the EU following leadership changes and consultant leave.
- Expense Increases: SG&A expenses rose $0.8 million to $3.5 million due to increased headcount (15 to 22 employees) and higher stock-based compensation ($91k vs $6k) from new option grants. R&D expenses increased $66k to $103k due to new hiring.
- Acquired IPR&D: The company recorded $119k in acquired in-process research and development expenses related to the Perikard, LLC asset acquisition (pericardial access patent).
- Fair Value Adjustment: A $1.16 million loss was recorded for the change in fair value of royalties payable due to related parties, primarily driven by a decrease in the discount rate used for valuation (from 29% to 21%).
- Tax Benefit: A $724k income tax benefit was recognized in Q1 2025, compared to none in Q1 2024, related to net operating losses not subject to Section 382 limitations.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for 12 months from the filing date. Cash on hand ($0.5M at quarter end) is insufficient to fund operations or repay the $1.5M related party note due in January 2026.
- Financing Needs: The company expects to need additional financing within the next month. It is evaluating debt and equity transactions, including a proposed at-the-market offering and private placements.
- Subsequent Events (Post-March 31):
- Cardionomic Acquisition: Closed May 5, 2025. Acquired late-stage heart failure treatment assets via 1M restricted shares and a $1.5M promissory note.
- May 2025 PIPE: On May 12, 2025, the company secured $1.5M in cash and $1.6M in defaulted notes (QHSLab) in exchange for Series B Convertible Preferred Stock and warrants.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties and review controls. A new CFO was hired in January 2025 to assist with remediation.
- Risks: Key risks include failure to secure financing, inability to achieve profitability, regulatory hurdles for new products, and reliance on key personnel.
Investor Verification Checklist
- Liquidity Runway: Verify the status of the May 2025 PIPE financing and whether the $1.5M cash proceeds are sufficient to cover the $1.5M related party note due Jan 31, 2026, and ongoing operating losses.
- Revenue Sustainability: Assess the recovery of VIVO System sales in the EU and the commercial traction of the new LockeT product to determine if revenue growth is sustainable.
- Related Party Obligations: Review the terms of the $1.5M related party notes and the $10.4M royalty liability payable to related parties (David A. Jenkins and affiliates) to understand future cash outflow obligations.
- Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in internal controls, particularly regarding financial reporting and tax provisions.
- Asset Acquisition Accounting: Review the Q2 2025 filing for the final accounting treatment of the Cardionomic asset acquisition, as provisional values were not available at the time of this filing.